Making Lifesaving Medicines Better

A stabilization platform that addresses some of drug delivery’s most difficult challenges

About Surf Bio

Surf Bio is a preclinical biopharmaceutical company leveraging a breakthrough next-generation surfactant to develop enhanced therapeutic solutions for diabetes, oncology, infectious diseases, gene therapy, and other therapeutic areas. 

Launched by the founders of Bigfoot Biomedical and Mode AGC, Surf Bio was founded to commercialize a breakthrough drug stabilization technology developed in the Appel Lab at Stanford University. Commercially, the technology is designed to enable reduction of refrigeration requirements, transition from IV to subcutaneous therapy, and novel pharmaceutical formulations across a range of therapeutic areas.

Cold Chain Mitigation

Mitigation of cold chain distribution requirements and extension of shelf life

Concentrating Formulations

Transitioning IV clinic treatments to outpatient subcutaneous injections

Enabling Formulations

Opening the door for commercialization of highly unstable therapeutics


We have a world-class team of scientists and entrepreneurs working to build the future of biopharmaceuticals.

Chief Executive Officer

Bryan Mazlish

Read Bio
President & Chief Medical Officer

Jennifer Schneider, MD

Read Bio
Chief Scientific Advisor

Eric Appel, PhD

Read Bio
Our Investors


Explore some of our recently-published therapeutics research


Surf Bio has established multiple, ongoing collaborations with leading multinational pharmaceutical companies. To date, demonstrated in-vitro and in-vivo safety and efficacy data has generated significant interest from partners to evaluate Surf Bio’s technology within their proprietary product pipelines. Proposed initial applications for the technology include increasing concentrations and reducing refrigeration dependence as well as enabling hard-to-formulate therapeutics.

Reach out to learn if Surf Bio’s technology can support your product pipeline.

Contact Us

Recent News

April 30, 2024

Surf Bio Announces $1.6 Million Non-Dilutive Grant

Read More
April 12, 2022

Surf Bio Announces $16 Million Series Seed Financing

Read More
July 1, 2021

Researchers Develop a New Ultrafast Insulin for Management of Blood Sugar in Diabetes

Read More

Contact Us

We’re always looking to engage with others who want to build a better future for humanity with pharmaceutical research and products.

Get in touch

Thank you for contacting Surf Bio.
We’ll be back in touch soon!
Oops! Something went wrong while submitting the form.